Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA
NCT06112548Completed
- Sponsor
- Damascus University
- Start
- Mar 2024
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of bupivacaine hydrochloride 0.75% injection, ketorolac and epinephrine in postoperative pain (2 arms), sponsored by Damascus University. Primary endpoints: Perception of pain at 48 hours, Functional status at 6 months and 2 more. Started Mar 2024; status: completed.
02
Drugs
bupivacaine hydrochloride 0.75% injectionketorolacepinephrine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06112548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112548.